COGT · Cogent Biosciences, Inc.

Cogent Biosciences’ Q1 2026 financial results reflect a deliberate acceleration of investment ahead of anticipated regulatory and commercial milestones for bezuclastinib. The $97.4 million net loss — up from $72.0 million year-over-year — was driven by a $12.3 million increase in R&D expenses, attributed explicitly to expanded early-stage programs, IND-enabling studies, Phase 1 clinical trials, and one-time wind-down costs for the FGFR program. G&A expenses surged $16.3 million year-over-year, with management citing organizational growth and activities tied directly to the planned commercial launch of bezuclastinib in both Systemic Mastocytosis and GIST. Notably, non-cash stock compensation accounted for $8.9 million of R&D and $8.0 million of G&A expenses — reflecting aggressive talent acquisition and retention efforts. Despite the widening loss, the company’s balance sheet remains exceptionally strong: $866.4 million in cash and marketable securities as of March 31, 2026 — a figure management states is sufficient to fund operations into 2028, including commercialization. This runway supports execution against near-term catalysts: FDA review of two NDAs (GIST under RTOR with Breakthrough Therapy designation; NonAdvSM with PDUFA date December 30, 2026), an upcoming oral presentation of pivotal PEAK trial data at ASCO 2026, and preparation for dual product launches in the second half of 2026. Management’s commentary underscores strategic focus on execution over cost containment, positioning the company at an inflection point where clinical validation is transitioning toward commercial viability.